- Stressed and Distracted, Kids and Their Teachers Say Virtual Learning Isn’t Working
- Fauci Says U.S. Will Stay With Two Doses of Pfizer, Moderna Vaccines
- Health Highlights, March 2, 2021
- Many Blacks, Hispanics Believe They’ll Get Worse Care If Dementia Strikes
- For Some Young Drivers, Smartphone Use Is One of Many Bad Habits
- Strep Throat Doesn’t Worsen Tourette But May Affect ADHD: Study
- Sports Position Doesn’t Affect Risk of Concussion-Linked CTE Illness
- ‘Telestroke’ Care at Hospitals Is Boosting Patient Outcomes
- Face Masks Won’t Impede Your Breathing, Study Confirms
- Pot May Not Be the Best Rx for a Migraine
Sprix Approved for Moderate-to-Severe Pain
MONDAY, May 17Roxro Pharma’s Sprix (ketorolac tromethamine) nasal spray has been approved by the U.S. Food and Drug Administration for the short-term treatment of moderate to moderately severe pain, the manufacturer said Monday in a news release.
The nasal spray contains the non-steroidal anti-inflammatory drug (NSAID) ketorolac. The non-narcotic medication minimizes the chances for abuse and eliminates side effects associated with narcotic pain relievers, the drug maker said.
The drug should not be used for longer than five days. Potential side effects may include peptic ulcers or gastrointestinal bleeding, and the drug shouldn’t be used in people who already have these conditions, a high risk of bleeding, or advanced renal failure, the company said.
Roxro is based in Menlo Park, Calif.
More information
The U.S. National Library of Medicine has more about pain relievers.
Source: HealthDay
